Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Future board change
Surgical Innovations Group plc (AIM: SUN) the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that Adam Power, Group Development Director, has provided twelve months' notice to the Board that he wishes to retire from his executive role as Group Development Director, with effect from 31 December 2021. The current intention is that he will subsequently continue to serve as a Non-executive Director for a further twelve months until 31 December 2022.
Commenting on the transition, Nigel Rogers, the Company's Chairman, said: "We are grateful to Adam for both his past and continuing commitment. These arrangements ensure that Adam can continue to devote his full commitment to current sales activities and supporting strategic business development, whilst allowing the Company sufficient time to manage a smooth transition in his Board and executive responsibilities."
For further information please contact:
| Surgical Innovations Group plc | |
| David Marsh, CEO | Tel: 0113 230 7597 |
| Charmaine Day, Co Sec & GFC | |
| | |
| N+1 Singer (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell (Corporate Finance) | |
| Rachel Hayes (Corporate Broking) | |
| | |
| Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com |
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.